Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the June 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

The CRSP US Mid Cap Index excludes the largest 70% and smallest 15% of US stocks by total market cap. CRSP buckets each eligible constituent in the corresponding growth or value index based on ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...